JP2012510798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510798A5 JP2012510798A5 JP2011538811A JP2011538811A JP2012510798A5 JP 2012510798 A5 JP2012510798 A5 JP 2012510798A5 JP 2011538811 A JP2011538811 A JP 2011538811A JP 2011538811 A JP2011538811 A JP 2011538811A JP 2012510798 A5 JP2012510798 A5 JP 2012510798A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancer
- compound
- seq
- angiopep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 238000000034 method Methods 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 208000008589 Obesity Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 108010064942 Angiopep-2 Proteins 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 230000008499 blood brain barrier function Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000004766 neurogenesis Effects 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 150000003141 primary amines Chemical class 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 1
- 208000011403 Alexander disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000022526 Canavan disease Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000008279 Dumping Syndrome Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 claims 1
- 206010057649 Endometrial sarcoma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000000527 Germinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 108010024118 Hypothalamic Hormones Proteins 0.000 claims 1
- 102000015611 Hypothalamic Hormones Human genes 0.000 claims 1
- 208000004356 Hysteria Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010052057 Neuroborreliosis Diseases 0.000 claims 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims 1
- 108090000189 Neuropeptides Proteins 0.000 claims 1
- 206010071323 Neuropsychiatric syndrome Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 102000006877 Pituitary Hormones Human genes 0.000 claims 1
- 108010047386 Pituitary Hormones Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000032395 Post gastric surgery syndrome Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000016624 Retinal neoplasm Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000021235 Schilder disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000030597 adult Refsum disease Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001925 catabolic effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000012839 conversion disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 230000002183 duodenal effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 201000008396 gallbladder adenocarcinoma Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 239000000960 hypophysis hormone Substances 0.000 claims 1
- 229940043650 hypothalamic hormone Drugs 0.000 claims 1
- 239000000601 hypothalamic hormone Substances 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000000297 inotrophic effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000004058 mixed glioma Diseases 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 208000002040 neurosyphilis Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 201000001219 parotid gland cancer Diseases 0.000 claims 1
- 239000000813 peptide hormone Substances 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 238000009101 premedication Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 201000008933 retinal cancer Diseases 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 208000002025 tabes dorsalis Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20094708P | 2008-12-05 | 2008-12-05 | |
| US61/200,947 | 2008-12-05 | ||
| PCT/CA2009/001781 WO2010063124A1 (en) | 2008-12-05 | 2009-12-07 | Peptide therapeutic conjugates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012510798A JP2012510798A (ja) | 2012-05-17 |
| JP2012510798A5 true JP2012510798A5 (cg-RX-API-DMAC10.html) | 2013-01-31 |
Family
ID=42232848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538811A Pending JP2012510798A (ja) | 2008-12-05 | 2009-12-07 | ペプチド治療剤コンジュゲートおよびその使用 |
Country Status (11)
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2260874A1 (en) | 2003-01-06 | 2010-12-15 | Angiochem Inc. | Aprotinin analogs as carriers across the blood-brain barrier |
| CA2597958C (en) | 2005-02-18 | 2019-01-15 | Angiochem Inc. | Molecules for transporting a compound across the blood-brain barrier |
| JP5436856B2 (ja) | 2005-07-15 | 2014-03-05 | アンジオケム インコーポレーティッド | 薬学的複合体における担体としてのアプロチニンポリペプチドの使用 |
| WO2008046228A1 (en) | 2006-10-19 | 2008-04-24 | Angiochem, Inc. | Compounds for stimulating p-glycoprotein function and uses thereof |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| CN102245642A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | Glp-1激动剂的结合物及其用途 |
| WO2010063122A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| CA2747220A1 (en) | 2008-12-17 | 2010-06-24 | Richard Beliveau | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| CN102510759A (zh) | 2009-04-20 | 2012-06-20 | 安吉奥开米公司 | 利用与血管肽-2类似物结合的抗癌剂治疗卵巢癌 |
| JP5932642B2 (ja) * | 2009-07-02 | 2016-06-08 | アンジオケム インコーポレーテッド | 多量体ペプチドコンジュゲートおよびその使用 |
| EP2509614A4 (en) * | 2009-12-07 | 2014-08-06 | Univ Ben Gurion | ANTIMICROBIAL WATER TREATMENT MEMBRANES AND MANUFACTURE THEREOF |
| CN102762589A (zh) | 2009-12-11 | 2012-10-31 | 卡斯西部储备大学 | 带有氯化氨基酸的胰岛素类似物 |
| WO2012115772A2 (en) | 2011-02-25 | 2012-08-30 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
| US20140249090A1 (en) * | 2011-04-01 | 2014-09-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. | Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders |
| JP6144673B2 (ja) | 2011-06-03 | 2017-06-07 | オフィディオン インコーポレイティド | 血液脳関門を通過して輸送するための組成物及び方法 |
| WO2013033675A1 (en) | 2011-09-02 | 2013-03-07 | Medtronic, Inc. | Chimeric natriuretic peptide compositions and methods of preparation |
| CU24076B1 (es) * | 2011-09-30 | 2015-01-29 | Ct De Ingeniería Genética Y Biotecnología | Composición para el control de patógenos |
| HK1204002A1 (en) * | 2011-12-01 | 2015-11-06 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
| BR112014013250A2 (pt) * | 2011-12-01 | 2019-09-24 | Angiochem Inc | compostos com enzima alvo e usos dos mesmos |
| WO2013104929A1 (en) * | 2012-01-12 | 2013-07-18 | University Of Ulster | Peptides and peptide derivatives based on xenin |
| KR20230113821A (ko) * | 2012-05-15 | 2023-08-01 | 씨젠 인크. | 자가-안정화 링커 접합체 |
| CA2876525A1 (en) * | 2012-06-15 | 2013-12-19 | Angiochem Inc. | Targeted iduromdase compounds |
| AU2013302270A1 (en) | 2012-08-14 | 2015-03-26 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
| JP6290212B2 (ja) | 2012-08-16 | 2018-03-07 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| JP6538561B2 (ja) | 2012-10-25 | 2019-07-03 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体Ｃ１ｓ抗体とそれらの用途 |
| PT2914291T (pt) | 2012-11-02 | 2022-05-05 | Bioverativ Usa Inc | Anticorpos anti-complemento c1s e suas utilizações |
| KR20140088837A (ko) * | 2013-01-03 | 2014-07-11 | 한미약품 주식회사 | Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체 |
| HK1219477A1 (zh) | 2013-03-21 | 2017-04-07 | Sanofi-Aventis Deutschland Gmbh | 合成含有乙内酰脲的肽产物 |
| EP2976325B1 (en) | 2013-03-21 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Synthesis of cyclic imide containing peptide products |
| MX370723B (es) | 2013-06-10 | 2019-12-20 | Ipierian Inc | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatía. |
| CA2931396C (en) | 2013-11-27 | 2022-09-06 | Ipierian, Inc. | An anti-tau antibody for treating tauopothy |
| US9957311B2 (en) | 2013-12-20 | 2018-05-01 | Tikomed Ab | Surface-binding peptide |
| US20170253643A1 (en) * | 2014-09-02 | 2017-09-07 | Tokyo University Of Science Foundation | Centrally-Acting Peptide Derivative, and Pharmaceutical Composition |
| EP3086120B1 (en) * | 2015-04-22 | 2019-07-31 | Euroimmun Medizinische Labordiagnostika AG | Diagnosis of a novel autoimmune disease |
| KR102808155B1 (ko) * | 2015-05-27 | 2025-05-16 | 노쓰웨스턴유니버시티 | 면역 반응 조절용 탄수화물-개질 입자 및 미립자 제제 |
| JP6823055B2 (ja) | 2015-06-15 | 2021-01-27 | アンジオケム インコーポレーテッド | 軟髄膜癌腫症の治療方法 |
| US10858410B2 (en) * | 2015-08-12 | 2020-12-08 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier |
| CN106466475B (zh) * | 2015-08-21 | 2021-06-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 抗菌肽与聚合物结合而成的复合物、其制备方法及用途 |
| NZ743368A (en) | 2015-12-16 | 2025-08-29 | Diet4Life Aps | Dietary peptides |
| US11530243B2 (en) * | 2016-02-18 | 2022-12-20 | Veiove Animal Health Inc. | Non-cleavable substance P conjugates and methods of use thereof |
| US10973812B2 (en) | 2016-03-03 | 2021-04-13 | Regents Of The University Of Minnesota | Ataxia therapeutic compositions and methods |
| IL295288B2 (en) | 2016-04-04 | 2024-08-01 | Bioverativ Usa Inc | Anti-complement factor BB antibodies and their uses |
| RU2748576C2 (ru) | 2016-04-19 | 2021-05-27 | Гриффон Фармасьютикалз Интернешнл Са. | Пэгилированные биологически активные пептиды и их применение |
| CN105801709B (zh) * | 2016-04-29 | 2019-10-08 | 北京纽莱福生物科技有限公司 | CBLB502-Fc融合蛋白及其制备方法 |
| TW202500191A (zh) | 2016-08-09 | 2025-01-01 | 美商思進公司 | 具有改善之生理化學性質之具自我穩定連接子之藥物結合物 |
| WO2018117613A1 (ko) * | 2016-12-19 | 2018-06-28 | 한미약품 주식회사 | 뇌 표적 지속성 단백질 결합체 |
| JP7295838B2 (ja) * | 2017-07-13 | 2023-06-21 | シティ・オブ・ホープ | ホスホロチオエートコンジュゲートペプチド及びその使用方法 |
| FR3070264A1 (fr) | 2017-08-24 | 2019-03-01 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| EP3675961A1 (en) * | 2017-08-31 | 2020-07-08 | University Of Dundee | Leptin peptides and their use for treating neurological disorders |
| CN107964047B (zh) * | 2017-12-18 | 2018-11-02 | 哈尔滨工业大学 | 基于内吗啡肽-1和神经降压素(8-13)的嵌合肽及其合成方法和应用 |
| CN110337302B (zh) * | 2018-01-15 | 2023-07-21 | 深圳市星银医药有限公司 | 一种马栗树提取物和利那洛肽组合物 |
| FI3746467T3 (fi) * | 2018-01-31 | 2026-01-16 | Sanofi Sa | Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö |
| CN108490178B (zh) * | 2018-02-13 | 2019-08-30 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于npc诊断及预后预测的标志物及其应用 |
| AU2019264092B2 (en) | 2018-05-04 | 2024-02-15 | Twinpigbiolab. Inc. | Targeting M2-like tumor-associated macrophages by using melittin-based pro-apoptotic peptide |
| US11090303B2 (en) | 2018-05-15 | 2021-08-17 | Lloyd Hung Loi Tran | Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders |
| CN114829383A (zh) * | 2019-06-06 | 2022-07-29 | 阿罗阿生物外科有限公司 | 生物活性剂及其相关方法 |
| BR112021026317A8 (pt) | 2019-06-26 | 2022-12-13 | Tran Dat | Análogos de teta-defensina |
| WO2021004539A1 (zh) * | 2019-07-11 | 2021-01-14 | 厦门大学 | 用于胞内递送分子的复合物 |
| CN110420317B (zh) * | 2019-07-25 | 2022-11-22 | 中国人民解放军军事科学院军事医学研究院 | Cblb502蛋白在防治创伤后应激障碍中的应用 |
| CN110437308B (zh) * | 2019-08-20 | 2023-05-05 | 倪京满 | 一类对铜绿假单胞菌具有特异活性的含β氨基酸的抗菌肽类似物及其应用 |
| CN110563802B (zh) * | 2019-09-04 | 2023-04-07 | 倪京满 | 一组含n-甲基化氨基酸及n端脂肪酸修饰的抗菌肽类似物及其合成方法和应用 |
| CN111808168A (zh) * | 2020-07-21 | 2020-10-23 | 南京农业大学 | 一类褐飞虱硫激肽类似物的合成及应用 |
| CN111704651B (zh) * | 2020-07-27 | 2021-10-08 | 南京安吉生物科技有限公司 | 具有抗衰老作用的多肽rv3和rv4及其应用 |
| CN114057831B (zh) * | 2020-08-07 | 2024-03-12 | 三凡生技研发股份有限公司 | 促进血管增生的短链胜肽及其促进糖尿病伤口愈合的用途 |
| KR20220076375A (ko) * | 2020-11-30 | 2022-06-08 | 세종대학교산학협력단 | 신규 퇴행성 신경질환 치료용 약학적 조성물 |
| CN112656953A (zh) * | 2020-12-30 | 2021-04-16 | 重庆医科大学 | 凝血酶响应型双靶向脂质体及其制备方法和应用 |
| CN112851789B (zh) * | 2021-02-04 | 2022-10-18 | 大理大学 | 一种脑靶向hiv进入抑制剂多肽及其应用 |
| IL305326A (en) * | 2021-02-22 | 2023-10-01 | Univ Yale | Targeted bifunctional degraders and methods for their use |
| CN113651874B (zh) * | 2021-08-02 | 2023-02-10 | 上海大学 | 一种具有抑制念珠菌生长繁殖作用的订书肽及其制备方法和应用 |
| KR102819567B1 (ko) * | 2021-11-24 | 2025-06-13 | 주식회사 윙스타바이오 | 아밀로이드 전구체 단백질에 대한 저해 활성을 갖는 펩타이드 및 이의 용도 |
| CN114250204B (zh) * | 2021-12-29 | 2024-02-09 | 深圳瑞德林生物技术有限公司 | 一种羧酸还原酶突变体及酶法合成脱羧肌肽的方法 |
| CN117186239A (zh) * | 2022-01-30 | 2023-12-08 | 南京瑞初医药有限公司 | 融合蛋白及其应用 |
| EP4525985A2 (en) * | 2022-05-16 | 2025-03-26 | The Children's Medical Center Corporation | Compositions and methods for treating a cardiac disease |
| CN115286694B (zh) * | 2022-06-02 | 2024-08-20 | 温州医科大学 | 一种南美青蛙宿主防御肽的衍生肽ps-pt-6f及其制备方法和应用 |
| CN115806740B (zh) * | 2022-11-17 | 2024-01-30 | 四川大学 | 一种集成多模态响应的导电水凝胶及其制备方法和用途 |
| CN116036234B (zh) * | 2023-01-17 | 2024-02-06 | 青岛市中心医院 | 一种用于治疗骨质疏松的药剂 |
| CN115948069B (zh) * | 2023-02-09 | 2024-11-29 | 广州工业智能研究院 | 一种双重抗菌超疏液涂层及其制备方法 |
| CN116298281A (zh) * | 2023-03-27 | 2023-06-23 | 山西农业大学 | 一种基于距离信号读出的胰蛋白酶含量检测方法 |
| CN116333041A (zh) * | 2023-04-10 | 2023-06-27 | 湖南中晟全肽生化有限公司 | 一种激活grp受体的多肽化合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040052814A1 (en) * | 1998-09-28 | 2004-03-18 | Wenyuan Shi | Fusion proteins for targeted delivery of antimicrobial peptides |
| US20040162284A1 (en) * | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
| CA2597958C (en) * | 2005-02-18 | 2019-01-15 | Angiochem Inc. | Molecules for transporting a compound across the blood-brain barrier |
| CN101511868B (zh) * | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| PL2164866T3 (pl) * | 2007-05-29 | 2014-10-31 | Angiochem Inc | Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek |
-
2009
- 2009-12-07 RU RU2011125366/10A patent/RU2011125366A/ru not_active Application Discontinuation
- 2009-12-07 JP JP2011538811A patent/JP2012510798A/ja active Pending
- 2009-12-07 EP EP09829936.5A patent/EP2794663A4/en not_active Withdrawn
- 2009-12-07 MX MX2011005964A patent/MX2011005964A/es unknown
- 2009-12-07 CN CN201310616186.9A patent/CN103665170A/zh active Pending
- 2009-12-07 WO PCT/CA2009/001781 patent/WO2010063124A1/en not_active Ceased
- 2009-12-07 US US13/133,002 patent/US20110288011A1/en not_active Abandoned
- 2009-12-07 BR BRPI0923283A patent/BRPI0923283A2/pt not_active IP Right Cessation
- 2009-12-07 AU AU2009322045A patent/AU2009322045A1/en not_active Abandoned
- 2009-12-07 CN CN200980156247XA patent/CN102348723A/zh active Pending
- 2009-12-07 CA CA2745499A patent/CA2745499A1/en not_active Abandoned
-
2011
- 2011-06-17 ZA ZA2011/04497A patent/ZA201104497B/en unknown
-
2015
- 2015-04-24 US US14/696,193 patent/US20160263235A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012510798A5 (cg-RX-API-DMAC10.html) | ||
| RU2011125366A (ru) | Конъюгаты терапевтических пептидов и их применение | |
| JP2012505637A5 (cg-RX-API-DMAC10.html) | ||
| RU2012103240A (ru) | Мультимерные пептидные конъюгаты и их применение | |
| RU2011118056A (ru) | Конъюгаты агонистов glp-1 и их применение | |
| JP7386218B2 (ja) | グルカゴン及びｇｌｐ－１共アゴニスト化合物 | |
| CN110088125B (zh) | 酰化的glp-1/glp-2双重激动剂 | |
| JP2012531467A5 (cg-RX-API-DMAC10.html) | ||
| EP2057188B1 (en) | Dpp-iv resistant gip hybrid polypeptides with selectable properties | |
| CA2943458C (en) | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID TUBE(S) | |
| US20100331245A1 (en) | Peptide yy analogs | |
| US20100016237A1 (en) | Novel Peptides for Use in the Treatment of Obesity | |
| US20090203581A1 (en) | Novel Peptides for Use in the Treatment of Obesity | |
| US20100056433A1 (en) | Novel Peptides for Use in the Treatment of Obesity | |
| JP2013534812A5 (cg-RX-API-DMAC10.html) | ||
| JP2015532297A (ja) | 二重ｇｌｐ１／グルカゴンアゴニストとしてのエキセンディン−４誘導体 | |
| JP2012529297A5 (cg-RX-API-DMAC10.html) | ||
| RU2011125367A (ru) | Конъюгаты лептина и аналогов лептина и их применение | |
| US20100016238A1 (en) | Peptides for Use in the Treatment of Obesity | |
| JP2015502918A5 (cg-RX-API-DMAC10.html) | ||
| CN115052615A (zh) | 肽缀合物和使用方法 | |
| WO2022247701A1 (zh) | 多激动剂及其应用 | |
| WO2025073222A1 (zh) | Glp-1r/gipr/gcgr三重激动剂类似物及其用途 | |
| CN115697414A (zh) | Glp1r激动剂nmdar拮抗剂缀合物 | |
| EA014647B1 (ru) | Гибридные полипептиды с селектируемыми свойствами |